Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Seres Therapeutics Inc MCRB

Healthcare Biotechnology
Seres Therapeutics, Inc. is a commercial-stage microbiome therapeutics company. It is focused on the development and commercialization of a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead program, VOWST, is to prevent recurrence of... see more

Recent & Breaking News (NDAQ:MCRB)

Seres Therapeutics, Inc. Announces Pricing of Public Offering of 10,500,000 Shares of Common Stock

Business Wire August 12, 2020

Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Business Wire August 11, 2020

Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection

Business Wire August 10, 2020

Seres Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates

Business Wire July 28, 2020

Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing

PR Newswire July 7, 2020

Seres Therapeutics Appoints Terri Young, Ph.D., R.Ph., Experienced Commercial Leader, as Executive Vice President, Chief Commercial and Strategy Officer

Business Wire June 22, 2020

Seres Therapeutics to Present at the Goldman Sachs 41st Annual Global Virtual Healthcare Conference

Business Wire June 2, 2020

Seres Therapeutics to Present at Jefferies Virtual Healthcare Conference

Business Wire May 28, 2020

Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity

PR Newswire May 28, 2020

Seres Therapeutics to Host Virtual SER-109 Focused Symposium on May 27, 2020, Ahead of Phase 3 ECOSPOR III Study Read-Out

Business Wire May 18, 2020

Seres Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates

Business Wire May 7, 2020

Seres Therapeutics to Host First Quarter 2020 Financial Results and Operational Progress Conference Call on May 7, 2020

Business Wire April 30, 2020

Seres Therapeutics Appoints Lisa von Moltke, M.D., as Chief Medical Officer

Business Wire April 6, 2020

Seres Therapeutics Announces Completion of Enrollment in SER-109 Phase 3 ECOSPOR III Study for Recurrent Clostridium difficile Infection and Provides Clinical Pipeline Updates

Business Wire March 30, 2020

Seres Therapeutics Appoints Paul Biondi, Experienced Biopharmaceutical Strategy and Corporate Development Professional, to Its Board of Directors

Business Wire March 23, 2020

Seres Therapeutics to Virtually Present at the Chardan Microbiome Medicines Summit

Business Wire March 15, 2020

Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration's March 12, 2020 Safety Alert Related to Use of Fecal Microbiota Transplantation

Business Wire March 13, 2020

Seres Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Highlights

Business Wire March 2, 2020

Seres Therapeutics to Present at the Cowen 2020 Health Care Conference

Business Wire February 25, 2020

Seres Therapeutics to Host Fourth Quarter 2019 Financial Results and Operational Progress Conference Call on March 2, 2020

Business Wire February 25, 2020